Clinical Trial Update: An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6) [Phase 3]

View source ↗

Summary

Open-label extension of cannabidiol (GWP42003-P) in seizures associated with tuberous sclerosis complex completed Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Seizures
• Tuberous Sclerosis Complex

Drugs mentioned

• Cannabidiol (GWP42003-P, CBD) (cannabidiol)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Tuberous Sclerosis Complex, Seizures | Phase 3 | Status: COMPLETED | Results posted: 2022-07-14